诺和诺德盘前涨超1% 拟以20亿美元购买广东药厂新型减肥药授权

金吾资讯
25 Mar

金吾财讯 | 诺和诺德(NVO)盘前涨超1%,截至发稿,报76.270美元。消息面上,诺和诺德周一宣布,与总部位于中国广东省的联邦制药达成独家许可协议,减肥药巨头掏钱购买中国药厂新型减肥药UBT251的海外(即不包含中国大陆和港澳台地区)开发、制造和商业化权利。首付款达到2亿美元,根据商业化进度还有最高18亿美元的里程碑付款。公开数据显示,UBT251是被称为“三靶点受体激动剂”的减重药物。除了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10